Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glomerulonephritis, IGA: full-pipeline trial registry
3 of 3 indexed Glomerulonephritis, IGA trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Glomerulonephritis, IGA: 3 US clinical trials tracked, 3 recruiting.
Glomerulonephritis, IGA is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition glomerulonephritis-iga
OPEN 3 | RECR 100% | LATE 1 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Glomerulonephritis, IGA lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glomerulonephritis, IGA on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glomerulonephritis, IGA is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
The Rogosin Institute
NCT01802034
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Novartis Pharmaceuticals
NCT06858319
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Novartis Pharmaceuticals
NCT06797518
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glomerulonephritis, IGA records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glomerulonephritis, IGA trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glomerulonephritis, IGA page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Glomerulonephritis, IGA trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Glomerulonephritis, IGA trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glomerulonephritis, IGA condition card totals 3 registered trials; most-linked intervention Iptacopan; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.